Adrenal Cancer — Expert Diagnosis, Targeted Treatment Access

Adrenal cancer refers to malignant tumors arising from the adrenal glands — two small glands sitting atop the kidneys that produce important hormones. The most common primary type is adrenocortical carcinoma (ACC), arising from the outer cortex. Malignant pheochromocytoma and paraganglioma arise from the inner medulla and related chromaffin tissue. Adrenal cancer is very rare, with adrenocortical carcinoma occurring in approximately 1–2 cases per million people per year worldwide.

Symptoms depend on whether the tumor produces hormones. Functional tumors may cause Cushing's syndrome (weight gain, purple stretch marks, high blood sugar, rounded face, muscle weakness) from cortisol excess; Conn's syndrome (high blood pressure, low potassium) from aldosterone excess; virilization and menstrual changes from androgen excess; or severe episodic hypertension, sweating, and palpitations from catecholamine excess (pheochromocytoma). Non-functional tumors may present only with abdominal or flank pain, or be found incidentally on imaging.

Pheochromocytoma produces adrenaline and related stress hormones. If a pheochromocytoma is not identified before a biopsy or surgery is performed, physical stimulation of the tumor can trigger sudden massive release of catecholamines, causing a life-threatening hypertensive crisis — with extreme blood pressure elevation, heart arrhythmias, and stroke risk. For this reason, all adrenal masses must undergo biochemical testing for catecholamine excess (plasma or urine metanephrines) before any invasive procedure.

Mitotane (also known as o,p'-DDD) is a medication that is toxic to adrenocortical cells and suppresses steroid hormone production. It is the only drug approved specifically for adrenocortical carcinoma. After surgical resection of ACC, mitotane is used as adjuvant therapy to reduce the risk of recurrence. In metastatic disease, it is combined with chemotherapy (typically etoposide, doxorubicin, and cisplatin in the EDP-M regimen). Mitotane requires careful blood level monitoring to ensure effectiveness while minimizing toxicity.

A meaningful proportion of adrenal cancers are linked to inherited genetic conditions. Adrenocortical carcinoma is associated with Li-Fraumeni syndrome (TP53 mutations) and Beckwith-Wiedemann syndrome. Malignant pheochromocytoma and paraganglioma are strongly associated with germline mutations in SDH subunit genes (particularly SDHB), VHL, RET, and others. All patients with adrenal cancer should be offered germline genetic testing and referral to a genetic counselor, both for their own management and for family surveillance.

Peptide Receptor Radionuclide Therapy (PRRT) — specifically 177Lu-DOTATATE — is a targeted nuclear medicine treatment that delivers radioactive lutetium directly to somatostatin receptor-expressing tumor cells. It is approved for treatment of metastatic, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors and is increasingly used for malignant pheochromocytoma and paraganglioma. Eligibility is confirmed by a positive 68Ga-DOTATATE PET scan showing adequate somatostatin receptor expression on the tumor. CancerFax can help coordinate access to PRRT centers internationally.

For metastatic adrenocortical carcinoma, the standard first-line systemic approach is the EDP-M regimen (etoposide, doxorubicin, cisplatin combined with mitotane). For patients who cannot tolerate EDP-M, streptozocin plus mitotane is an alternative. Locoregional therapies (ablation, TACE) may be used for isolated liver metastases. Clinical trials evaluating CDK4/6 inhibitors, immune checkpoint inhibitors, and targeted agents are actively recruiting. For metastatic pheochromocytoma, options include CVD chemotherapy, sunitinib, 131I-MIBG, and 177Lu-DOTATATE PRRT.

Post-treatment surveillance for ACC includes regular CT imaging of the chest, abdomen, and pelvis (typically every 3 months for the first 2 years, then less frequently), ongoing hormonal testing to detect functional recurrence, and mitotane plasma level monitoring if on adjuvant therapy. For pheochromocytoma, plasma or urine metanephrines and functional imaging (68Ga-DOTATATE or 123I-MIBG) are used to monitor for recurrence or metastatic progression. Genetic surveillance for hereditary syndrome-related tumors is lifelong.

Yes. CancerFax specializes in supporting patients with rare and complex cancers like adrenal cancer. We can review your imaging reports, hormonal panels, pathology results, and molecular profiling findings, then connect you with specialist endocrine oncologists, adrenal surgeons, and multidisciplinary teams — including internationally in India, Germany, the UAE, and other countries with expertise in adrenal malignancies. We assist with second opinion coordination, identification of clinical trial opportunities, access to PRRT and 131I-MIBG programs, and end-to-end support for patients seeking advanced treatment options.